Loading…
Ind-Swift Laboratories (INDSWFTLAB)₹349.05+3.59%Pharmaceuticals
At the end of the Sep 2026 quarter, Ind-Swift Laboratories' shareholders were: promoters 42.91%, FIIs 10.79%, DIIs 0.20%, public 46.10%. Promoter holding is unchanged on the quarter. FII holding is down 4.02 percentage points from 14.81% a year earlier. 0.00% of promoter shares were pledged. It had 42,665 shareholders.
As of · Company filings (shareholding pattern)
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 41.99% | 41.99% | 41.99% | 41.99% | 41.99% | 40.92% | 40.92% | 39.47% | 39.47% | 42.98% | 42.91% | 42.91% |
| FIIs | 0.31% | 0.26% | 1.28% | 0.65% | 0.46% | 3.08% | 4.28% | 14.81% | 14.34% | 13.89% | 10.71% | 10.79% |
| DIIs | 18.75% | 8.05% | 0.94% | 0.94% | 0.94% | 0.91% | 0.91% | 0.68% | 0.68% | 0.00% | 0.17% | 0.20% |
| Public | 38.95% | 49.70% | 55.79% | 56.42% | 56.61% | 55.09% | 53.89% | 45.04% | 45.51% | 43.13% | 46.21% | 46.10% |
| Promoter shares pledged | — | — | — | — | — | — | — | — | — | — | — | 0.00% |
| Number of shareholders | 24,632 | 22,438 | 25,460 | 28,882 | 28,751 | 28,116 | 28,708 | 43,778 | 42,119 | 39,220 | 40,879 | 42,665 |
| Holder | Category | Sep 2026 | Change (pp) |
|---|---|---|---|
| Essix Biosciences Limited | Promoter | 37.83% | 0.00 |
| Zeal Global Opportunities Fund | FII | 4.60% | 0.00 |
| Nova Global Opportunities Fund Pcc - Touchstone | FII | 3.30% | +0.36 |
| Panchkula Finvest Private Limited | Public | 2.47% | +0.07 |
| Ashokkumar Chandak | Public | 2.44% | +0.22 |
| Zaki Abbas Nasser | Public | 2.01% | −0.11 |
| Pranav Joneja | Public | 1.43% | 0.00 |
| Ark Global Emerging Companies, Lp | FII | 1.39% | +0.27 |
| Sharwan Singh Guleria | Public | 1.31% | +0.08 |
| Navrattan Munjal | Promoter | 1.15% | 0.00 |
| Rameshkumar Javerchand Jain | Public | 1.13% | −0.24 |
| Rishav Mehta | Promoter | 1.09% | 0.00 |
| Nisarg Ajaykumar Vakharia | Public | 1.05% | 0.00 |
| Chetan Chandak | Public | 1.03% | New |
| Manish Chandak | Public | 1.02% | New |
| S. R. Mehta | Promoter | 0.62% | 0.00 |
| Himanshu Jain | Promoter | 0.55% | 0.00 |
| Gopal Munjal | Promoter | 0.41% | 0.00 |
| V.R. Mehta | Promoter | 0.39% | 0.00 |
| Sunita Jain | Promoter | 0.37% | 0.00 |
| Ravi Mehta | Promoter | 0.12% | 0.00 |
| Neeta Munjal | Promoter | 0.11% | 0.00 |
| Nidhi Munjal | Promoter | 0.10% | 0.00 |
| Meenakshi Mehta | Promoter | 0.08% | 0.00 |
| Annie Mehta | Promoter | 0.03% | 0.00 |
Promoters held 42.91% of Ind-Swift Laboratories at the end of the Sep 2026 quarter, up 3.44 percentage points from 39.47% a year earlier.
In the Sep 2026 quarter, foreign institutional investors (FIIs) held 10.79% (up 0.08 percentage points from 10.71% a quarter earlier) and domestic institutions (DIIs) held 0.20% (up 0.03 percentage points from 0.17% a quarter earlier).
No. The Sep 2026 filing shows no pledged promoter shares.
Ind-Swift Laboratories had 42,665 shareholders at the end of the Sep 2026 quarter, against 43,778 a year earlier.
Zeal Global Opportunities Fund (FII) held 4.60% at the end of the Sep 2026 quarter, the largest named holding outside the promoter group.